Pharma major Lupin and Glenmark Pharma have received a USFDA nod for an Alzheimer’s drug. Surajit Pal, analyst, Prabhudas Lilladher believes the same won’t have too much impact on either company.
Pal continues to have a positive outlook on Glenmark with a target price of Rs 1186 per share.
Watch video for more.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
